Kevin K.  Buckbee net worth and biography

Kevin Buckbee Biography and Net Worth

SVP of AbbVie
Kevin Buckbee is Senior Vice President, Corporate Controller. A member of AbbVie’s Executive Leadership Team, Mr. Buckbee is responsible for all global financial planning and reporting of the company.  Previously, he served as Vice President, Controller for Global Commercial Operations.

Mr. Buckbee joined Abbott in 1991 and held various leadership positions in the company across its pharmaceutical, diagnostic, nutrition and hospital product businesses.  Immediately prior to AbbVie’s separation from Abbott in 2013, he was appointed Vice President, Controller for U.S. Commercial Operations.  Mr. Buckbee began his career at Ernst & Young.  

Mr. Buckbee earned a bachelor’s degree in accounting from Miami University (Ohio).  He is also a Certified Public Accountant.

What is Kevin K. Buckbee's net worth?

The estimated net worth of Kevin K. Buckbee is at least $1.18 million as of February 29th, 2024. Buckbee owns 6,983 shares of AbbVie stock worth more than $1,177,264 as of June 15th. This net worth estimate does not reflect any other investments that Buckbee may own. Learn More about Kevin K. Buckbee's net worth.

How do I contact Kevin K. Buckbee?

The corporate mailing address for Buckbee and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Kevin K. Buckbee's contact information.

Has Kevin K. Buckbee been buying or selling shares of AbbVie?

Kevin K. Buckbee has not been actively trading shares of AbbVie during the last ninety days. Most recently, Kevin K. Buckbee sold 5,144 shares of the business's stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $176.65, for a transaction totalling $908,687.60. Following the completion of the sale, the senior vice president now directly owns 6,983 shares of the company's stock, valued at $1,233,546.95. Learn More on Kevin K. Buckbee's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Kevin Buckbee (SVP), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 11 times. They sold a total of 404,736 shares worth more than $70,989,822.24. The most recent insider tranaction occured on March, 20th when EVP Nicholas Donoghoe sold 21,082 shares worth more than $3,716,756.60. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 3/20/2024.

Kevin K. Buckbee Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/29/2024Sell5,144$176.65$908,687.606,983View SEC Filing Icon  
See Full Table

Kevin K. Buckbee Buying and Selling Activity at AbbVie

This chart shows Kevin K Buckbee's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $168.59
Low: $166.00
High: $169.24

50 Day Range

MA: $163.56
Low: $154.86
High: $170.43

2 Week Range

Now: $168.59
Low: $130.96
High: $182.89

Volume

3,933,662 shs

Average Volume

5,477,690 shs

Market Capitalization

$297.71 billion

P/E Ratio

50.03

Dividend Yield

3.73%

Beta

0.6